To view a copy of this licence, visit About this article Cite this article Detka, J., Gombik, K
If youre experiencing hair loss while taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, know that many women have gone through the same experience
Dosing fundamentals Administration: Once weekly subcutaneous injection Same day each week (consistency matters) Preferably at the same time of day Half-life: Approximately 6 days, supporting weekly dosing Dose escalation: Every 4 weeks, unless: Side effects require holding current dose Individual tolerance suggests faster/slower progression Healthcare provider recommends adjustment Clinical trial doses tested The Phase 2 obesity trial tested multiple dosing arms: Key insight: 8 mg produces nearly the same results as 12 mg with fewer side effectsmaking it a potential "sweet spot" for many users
Side effects were mostly mild
Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans